Progen Pharmaceuticals
Progen Pharmaceuticals

Board of Directors

The Board's experience and skills are complimentary and diverse, bringing together commercial, scientific, medical and legal expertise.


Mr Stuart James BA Honours

Chairman

Mr. James has held a number of high profile executive positions during his career and has extensive experience in the oil, health and financial services sector.  Following a 25 year career with Shell both in Australia and internationally, Mr. James past roles have included Managing Director of Australian Financial Services for Colonial and Managing Director of Colonial State Bank (formally the State Bank of N.S.W).  Mr. James most recent executive role was a C.E.O of The Mayne Group, including Mayne Health and Mayne Pharma.  He is a Member of the Supervisory Board of Wolters Kluwer NV  and a member of the Advisory Board of Gresham Private Equity Ltd.  Mr, James is Chairman of Pulse Health Ltd., Prime Financial Group Ltd and a Non Executive Director of Greencross Ltd. 


Mr Heng Hsin Tang BENG(Hons) MBA

Non-Executive Director

Mr Tang has a bachelor’s degree in Civil Engineering with honours, and an MBA from the University of Queensland. Mr Tang has more than 10 years experience in project and financial managements in engineering and property development, specialising in feasibility studies, cash-flow management, structural finance and acquisitions for major projects. Until recently, Mr Tang was Commercial Manager for a national property developer, and managed the finance for their Queensland projects valued at over $1bn.


Dr. Woei-Jia Jiang BSc, MSc. PhD, MAICD 

Non-Executive Director

Dr Jiang is a bioentrepreneur with more than 20 years experience in the pharmaceutical and biotechnology industries working in research, corporate advisory and various senior management roles. Currently he is the Managing Director of Wholesome Biopharm Pty Ltd, a Melbourne-based biotechnology company focused on the development of innovative asthma treatments.  Dr. Jiang was a co-founder of Metabolic Pharmaceuticals Limited, now Calzada Limited (ASX: CZD) when his co-invention of AOD9604 was out-licensed to Circadian Technologies Limited (ASX: CIR) and he has also consulted to biotechnology companies locally and internationally, including former Meditech Research Limited (now Alchemia Oncology Pty Ltd., a subsidiary of Alchemia Limited; ASX: ACL). Dr. Jiang received his BSc and MSc (Chemistry) degrees from National Cheng-Kung University in Taiwan and PhD (Biochemistry) degree from Monash University, Australia.


 

 

 

 

 

 

Home Our Company Our Technology Our Pipeline Investor Centre